Validation Data Gallery
Tested Applications
Positive FC detected in | HepG2 cells |
Recommended dilution
Application | Dilution |
---|---|
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
98383-2-RR targets FGFR4 in FC applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Recombinant |
Type | Antibody |
Immunogen | Recombinant protein 相同性解析による交差性が予測される生物種 |
Full Name | fibroblast growth factor receptor 4 |
Calculated molecular weight | 88 kDa |
GenBank accession number | BC011847 |
Gene Symbol | FGFR4 |
Gene ID (NCBI) | 2264 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
UNIPROT ID | P22455 |
Storage Buffer | PBS with 0.09% sodium azide , pH 7.3 |
Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
Background Information
Fibroblast growth factor receptor 4 (FGFR4) is a member of a highly conserved tyrosine kinase family, along with FGFR1-3. This family consists of an intracellular tyrosine kinase domain, a single transmembrane domain, and extracellular ligand binding domains (PMID:32492514). FGFR4 is the predominant FGFR isoform present in human hepatocytes. FGFR4 has been proposed to play a role in the observed induction of hepatocyte proliferation and carcinogenesis by FGF19; however, contradicting evidence proposing a protective role for FGFR4 in suppressing hepatoma progression has also been proposed(PMID:20018895). While the role of FGFR4 in cancer remains to be fully elucidated, several findings suggest that this receptor may be an important player in Hepatocellular carcinoma (HCC) development and/or progression (PMID:10336501).
Protocols
Product Specific Protocols | |
---|---|
FC protocol for FGFR4 antibody 98383-2-RR | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |